Evangeline Gonzalez Joins Ubiquitome Board of Directors
News Feb 19, 2015
Ubiquitome Limited, announced at the Molecular Medicine Triconference in San Francisco, that Evangeline Gonzalez, has joined its Board of Directors. Ubiquitome’s Freedom4 is the first commercially available handheld, mobile device to offer gold standard real-time PCR performance wherever it is needed. The company recently established a partnership with Integrated DNA Technologies (IDT) to develop the Ubiquitome Freedom4 real-time RT-PCR Ebola Virus Assay.
Paul Pickering, Ubiquitome CEO, said “Evangeline has proven expertise in market and product development from leading international biotechnology companies. Her insight and commercialization experience will be a huge asset to our team as we continue to establish Freedom4 in the marketplace.”
Gonzalez is currently the Senior Vice President of Marketing at Beckman Coulter, a Danaher company, responsible for facilitating growth and marketing strategy for the Diagnostics Division. She began her career at Pharmacia Biotech as a research associate developing products for protein separation. She has worked in R&D, Product Marketing and Strategic Market & Business Development, holding various assignments of increasing responsibility at Genentech, Life Technologies and Advanced Cell Diagnostics. Gonzalez has a BA in chemistry, BS in biochemistry and an MBA in marketing/entrepreneurship from San Francisco State University.
“I’m delighted to join Ubiquitome’s board and be integrally involved in the key strategies and decisions that will help advance broad utilization of the Freedom4,” said Gonzalez. “The device is positioned to gain strong traction in channels where no other of its kind exists.”
Fitting in the palm of a hand, Ubiquitome’s Freedom4 instrument operates on battery power alone for up to six hours and delivers gold-standard real-time PCR performance wherever needed. The platform runs using an iPhone or laptop computer, is housed in a rugged aluminum casing and features a solid state design that includes laser-based optical detection, which is widely recognized as offering the highest performance in real-time PCR.
Massachusetts General Hospital (MGH) researchers have found that extracellular RNA (exRNA) in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.READ MORE